ALPCO to Feature New STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and Young Investigators Travel Grant Program at ADA’s 78th Scientific Sessions
ALPCO will promote its new STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and Young Investigators Travel Grant Program at the American Diabetes Association’s 78th Scientific Sessions June 23-25, 2018 in Orlando, FL.
InSphero Partners with ALPCO to Advance Diabetes Research
InSphero extends 3D InSight™ Diabetes Discovery Platform to include ALPCO STELLUX® Chemiluminescent ELISA technology for assessment of pancreatic β-cell function.
Researchers Offer Inspiration and Advice for World Diabetes Day
In recognition of the World Diabetes Day 2017 theme: "Women and Diabetes", we asked researchers Dr. Darleen Sandoval, Dr. Lori Sussel, and Dr. Christine Doucette to share their career inspiration and advice for aspiring investigators.
Leveraging Non-Invasive Approaches in NAFLD and NASH Diagnosis and Clinical Research
Dr. Sabina Paglialunga of Celerion addresses the merits and limitations of non-invasive NAFLD/NASH diagnosis and treatment monitoring modalities such as ultrasound, magnetic resonance and elastography. Panels of soluble biomarkers that can distinguish between advanced fibrosis, NASH and fatty liver are also discussed.
ALPCO Offering Demonstrations of STELLUX® Chemiluminescent Plate Reader at ADA 2017
The STELLUX® Chemiluminescent Plate Reader offers a simple plug-and-play setup, and is the ideal size for any lab. ALPCO’s Field Applications Scientist will be on-site at the ADA’s 77th Scientific Sessions offering live demonstrations of the new STELLUX® Chemiluminescent Plate Reader.